3rd mRNA-Based Therapeutics Summit Europe | Berlin, Germany | 23rd-25th January 2024

The eagerly anticipated mRNA-Based Therapeutics Summit Europe returns to Berlin this January for the third year as Europe's largest and most important gathering of mRNA experts.

Showcasing exclusive new data from the trailblazers and thought leaders in the field, join 250+ industry specialists including the likes of the MHRA, EMA, BioNTech, CureVac, Ziphius Vaccines, Moderna and more across 3 days to uncover groundbreaking discovery, pre-clinical and clinical insights in mRNA therapeutic and vaccine development to fast-track R and D and pipeline expansions.

URLs:
Website: https://go.evvnt.com/1951095-0?pid=10018
Tickets: https://go.evvnt.com/1951095-2?pid=10018
Brochure: https://go.evvnt.com/1951095-3?pid=10018

Prices:
Conference + Focus Day OR Workshop Day - Drug Developer Pricing: EUR 4446.00,
Conference Only - Drug Developer Pricing: EUR 2799.00,
Conference + Focus Day OR Workshop Day - Small Biotech Pricing: EUR 4246.00,
Conference Only - Small Biotech Pricing: EUR 2799.00,
Conference + Focus Day OR Workshop Day - Academic Pricing: EUR 3896.00,
Conference Only - Academic Pricing: EUR 2399.00,
Conference + Focus Day OR Workshop Day - Service Provider Pricing: EUR 5446.00,
Conference Only - Service Provider Pricing: EUR 3499.00

Speakers: Ajan Reginald Chief Executive Officer Roquefort Therapeutics plc, Alexander Zehnder CEO CureVac, Amit Benazraf Business Development Lead Mana Bio, Anette Sommer Senior Director, Emerging Science and Innovation, Lead Oncology Europe Pfizer, Arun Kumar Preclinical Vaccines Development Lead CEPI, Carsten Rudolph CEO Ethris, Chris Cardon CEO Ziphius Vaccines, Claudia Lindemann Director - Non-Clinical Safety BioNTech SE, Covadonga Paneda Chief Operating Officer Altamira Therapeutics, Daniel Tondera Head of Biology Pantherna Therapeutics, Duccio Medini R3 Program Director Wellcome Leap, Estelle Beguin Director - Technology Research Ethris, Fernando Ulloa Montoya Head - Data and Computational Science mRNA Center of Excellence, Sanofi, Gad Berdugo Managing Partner; Strategic Advisor Explorium Capital LLC; Nutcracker Therapeutics, Jenny van Asbeck CEO Mercurna, Jens Demand Director - Product Life Cycle PATH, Jerry Zhang Vice President - Formulation Research and Development Abogen Biosciences, Ka-Wai Wan Senior Pharmaceutical Assessor Medicines and Healthcare Products Regulatory Agency (MHRA), Marco Cavaleri Head of Biological Health Threats and Vaccines Strategy European Medicines Agency, Maren von Fritschen Head - Regulatory Policy Europe Moderna, Martin Friede Initiative for Vaccine Research Coordinator World Health Organization - WHO, Martin Friede Initiative for Vaccine Research Coordinator World Health Organization - WHO, Myriam Mendila Chief Development Officer CureVac, Rajesh Krishnan Director of Formulations Providence Therapeutics Inc., Sam Deutsch Executive Vice President, Research and Early Development Nutcracker Therapeutics, Sanjay Singh CEO Gennova Biopharmaceuticals, Simone Blayer Global Head - CMC PATH, Sonia Golombek Senior Research and Development Manager Elastrin Therapeutics, Sven Jager Computational Science Manager Sanofi, Swarnendu Kaviraj Associate Director - R and D Gennova Biopharmaceuticals, Thomas Langenickel Chief Medical Officer Ethris GmbH, Tim Sparey Managing Director VaxEquity, Wade Davis VP - Computational Science Moderna, Yaniv Erlich CEO Eleven Therapeutics, Ana Rebane Professor University of Tartu, Camilla Foged Professor University of Copenhagen, Chantal Pichon Professor and Head of Research unit University of Orleans, Lorenzo Franceschini Co-Founder / mRNA Development and Production Lead Vrije University Brussels, Mark Dickman Professor University of Sheffield, Nawaz Muhammad Senior Scientist University of Salzburg, Simone Spuler Professor Charité Universitätsmedizin Berlin, Tim Beissert Head Immune and Gene Therapy Development TRON, Ioana Panait Research Analyst Beacon Targeted Therapies, Matthias Lubbert Principle Engineer - Process KNAUER Wissenschaftliche Geräte GmbH, May Guo Chief Commercial Officer Areterna